Company news

Fulcrum Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

January 9, 2022

Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer

January 3, 2022

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

December 5, 2021

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

November 16, 2021

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

November 3, 2021

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

November 2, 2021

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8: 00 a.m. ET

October 27, 2021

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2021

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

September 19, 2021

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

September 7, 2021

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

September 1, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

August 15, 2021

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

August 10, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

August 9, 2021

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

August 9, 2021

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8: 00 a.m. ET

August 3, 2021

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

June 23, 2021

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

June 20, 2021

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

May 11, 2021

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

May 6, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

May 5, 2021

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

May 5, 2021

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8: 00 a.m. ET

April 28, 2021

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

April 8, 2021

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

March 23, 2021

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

March 17, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

March 3, 2021

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8: 00 a.m. ET

February 25, 2021

Fulcrum Therapeutics Recognizes Rare Disease Day 2021

February 25, 2021

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

February 18, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

January 21, 2021

Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

January 18, 2021

Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference

January 5, 2021

Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease

December 8, 2020

Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

December 4, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

November 9, 2020

Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

November 3, 2020

Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8: 00 a.m. ET

November 2, 2020

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

October 4, 2020

Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society

September 30, 2020

Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting

September 24, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

August 10, 2020

Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

August 10, 2020

Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8: 00 a.m. ET

August 4, 2020

MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

July 20, 2020

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

June 23, 2020

Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19

June 9, 2020

Fulcrum Therapeutics Completes $68.5 Million Private Placement

June 9, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.